A health economic model to assess the cost-effectiveness of PEG IFN ?-2a and ribavirin in patients with mild chronic hepatitis C-Reference-Cited by-同舟云学术

A health economic model to assess the cost-effectiveness of PEG IFN ?-2a and ribavirin in patients with mild chronic hepatitis C

Published:2007-08 Issue:8 Volume:14 Page:523-536
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Gerkens S.,Nechelput M.,Annemans L.,Peraux B.,Mouchart M.,Beguin C.,Horsmans Y.

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2006.00831.x/fullpdf

Reference34 articles.

1. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.

2. 3F Renard, M Autier, and D Doumont . L'hepatite C en Belgique, comment ameliorer le depistage et la prevention ? Belgique: Ecole de sante Publique, Unite d'Education pour la sante, Serie de dossiers techniques CFB, Report No. 05-34, 27 pp.

3. Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6;BMC Gastroenterology;2016-08-05

2. Cost-effectiveness of boceprevir co-administration versus peginterferon alpha-2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore;Antiviral Therapy;2014

3. The Effect of Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an Integrated Care Setting;Journal of Managed Care Pharmacy;2013-07

4. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients;Hepatitis Monthly;2013-06-19

5. Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C;Clinical Infectious Diseases;2012-03-12